Plasma homocysteine level in patients with Behcet's disease with or without thrombosis

Archives of Iranian Medicine

Volumn 13, Issue 6, 2010, Pages 476-481

  Shahram, Farhad ^a   Faridar, Alireza ^a   Hamedani, Mohammad Ghaffari ^a   Nadji, Abdolhadi ^a   Naderi, Nassim ^a   Shafiee, Niloofar Mojarad ^a   Rasker, Johannes J ^b   Davatchi, Fereydoun ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Behcet's disease; HLA B51; Homocysteine; Thrombosis

Indexed keywords

HLA B ANTIGEN; HLA B27 ANTIGEN; HLA B5 ANTIGEN; HLA B51 ANTIGEN; HOMOCYSTEINE; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ABDOMINAL AORTA EMBOLISM; ABDOMINAL AORTA THROMBOSIS; ADULT; AMINO ACID BLOOD LEVEL; ANGIOGRAPHY; ANTIGEN DETECTION; AORTA DISSECTION; AORTA THROMBOSIS; ARTICLE; BEHCET DISEASE; CAVERNOUS SINUS THROMBOSIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; EMBOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; EYE INJURY; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; IRAN; JOINT; MAJOR CLINICAL STUDY; MALE; PHLEBITIS; PLASMA HOMOCYSTEINE LEVEL; RISK FACTOR; SEX DIFFERENCE; SKIN DEFECT; SUPERIOR CAVA VEIN OBSTRUCTION; THROMBOSIS;

ADULT; BEHCET SYNDROME; FEMALE; HLA-B ANTIGENS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THROMBOSIS;

EID: 78649433901     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lie JT. Vascular involvement in Behcet's disease: arterial and venous and vessels of all sizes. J Rheumatol. 1992; 19: 341-343.
2. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999; 341: 1284-1291.
3. Leiba M, Sidi Y, Gur H, Leiba A, Ehrenfeld M. Behcet's disease and thrombophilia. Ann Rheum Dis. 2001; 60: 1081-1085.
4. Shahram F, Nadji A, Jamshidi A, Davatchi F. Large vessel involvement in Behcet's disease. Acta Med Iran. 2004; 42: 158-162.
5. Koc Y, Gullu I, Akpec G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behcet's disease. J Rheumatol. 1992; 19: 402-410.
6. Gul A, Ozbec U, Ozturk C, Inanc M, Konice M, Ozcelik T, et al. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's disease. Br J Rheumatol. 1996; 35: 1178-1180.
7. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The longterm mortality and morbidity of Behcet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003; 82: 60-76.
8. Calamia K, Schirmer M, Melikoglu M. Major vessel involvement in Behcet's disease. Curr Opin Rheumatol. 2005; 17: 1-8.
9. Kosar A, Haznedaroglu I, Buyukasik Y, Kirazly S, Dundar S. Activated protein C resistance in Behcet's disease. Rheumatol Int. 1988; 17: 249-250.
10. Nalcaci M, Pekcelen Y. Antithrombin III, protein C, and protein S plasma levels in patients with Behcet's disease. J Med Res. 1998; 26: 206-208.
11. Navarro S, Ricart J, Medina P, Vaya A, Villa P, Todoli J, et al. Activated protein C level in Behcet's disease and risk of venous thrombosis. Br J Haematol. 2004; 126: 550-556.
12. Kwon S, Lim M, Park S, Moon Y, Park W. Decreased protein S activity is related to the disease activity of Behcet's disease. Rheumatol Int. 2006; 27: 39-43.
13. Al-Daalan A, Al-Ballaa S, Al-Janadi M, Bholega S, Bhabri S. Association of anticardiolipin antibodies with vascular thrombosis and neurological manifestation of Behcet's disease. Clin Rheumatol. 1993; 12: 28-30.
14. Priori R, Conti F, Pittoni V, Garofalo T, Sorice M, Valesini G. Is there a role for antiphospholipid binding protein antibodies in the pathogenesis of thrombosis in Behcet's disease? Thromb Haemost. 2000; 83: 173-174.
15. Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behcet's disease: a reassessment. Rheumatology (Oxford). 2001; 40: 192-195.
16. Guerey A, Gurler A, Oner A, Mesci L, Kirazli S. Thrombomodulin levels in Behcet's disease with and without factor V Leiden mutation. Clin Rheumatol. 1998; 17: 186-188.
17. Gurgey A, Balta G, Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease. Blood Coagul Fibrinolysis. 2003; 14: 121-124.
18. Leiba M, Seligsohn U, Sidi Y, Harats D, Sela B, Griffin J, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis. 2004; 63: 1445-1449.
19. Altinbas A, Aytemur K, Tokgozoglu L, Ozturk M, Kosar A, Haznedaroglu I, et al. Hyperhomocysteinemia and activated protein C resistance in Behcet's disease. J Intern Med. 2000; 248: 267-269.
20. Aksu K, Turgan N, Oksel F, Keser G, Ozmen D, Kitapcioglu G, et al. Hyperhomocysteinemia in Behcet's disease. Rheumatology (Oxford). 2001; 40: 687-690.
21. Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behcet's disease. Rheumatol Int. 2003; 23: 236-240.
22. Ates A, Aydintug O, Olmez U, Duzgun N, Duman M. Serum homocysteine level is higher in Behcet's disease with vascular involvement. Rheumatol Int. 2005; 25: 42-44.
23. Hankey G, Eikelboom J. Homocysteine and vascular disease. Lancet. 1999; 354: 407-413.
24. Mungan A, Can M, Acikgoz S, Esturk E, Altinyazar C. Lipid peroxidation and homocysteine levels in Behcet's disease. Clin Chem Lab Med. 2006; 44: 1115-1118.
25. Ozkan Y, Yardim-Akaydin S, Sepici A, Engin B, Sepici V, Simsek B. Assessment of homocysteine, neopterin, and nitric oxide levels in Behcet's disease. Clin Chem Lab Med. 2007; 45: 73-77.
26. Ozdemir R, Barutcu I, Sezgin A, Acikgoz N, Ermis N, Esen A, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol. 2004; 94: 522-525.
27. International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990; 335: 1078-1080.
28. Sarican T, Ayabakan H, Turkmen S, Kalaslioglu V, Baran F, Yenice N. Homocysteine: an activity marker in Behcet's disease? J Dermatol Sci. 1990; 45: 121-126.
29. Woo K, Chook P, Lolin Y, Cheung A, Chan L, Sun Y, et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997; 96: 2542-2544.
30. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997; 90: 1-11.
31. Ricart J, Vaya A, Todoli J, Calvo J, Villa P, Estelles A, et al. Thrombophilic risk factors and homocysteine level in Behcet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost. 2006; 95: 618-624.
32. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta- analysis of published epidemiological studies. J Thromb Haemost. 2005; 3: 292-299.
33. Shahram F, Davatchi F, Nadji A, Jamshidi A, Bahar K, Akbarian M, et al. Association of HLA-B51 with clinical expression of Behcet's disease, analysis of 201 Iranian patients. Adv Exp Med Biol. 2003; 528: 147-148.